Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
Author:
Affiliation:
1. Division of Hematology Oncology, University of California, Los Angeles, USA
2. Division of Hematology Oncology, University of California, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA 90095, USA
Abstract
Publisher
SAGE Publications
Subject
Oncology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1758834014539183
Reference32 articles.
1. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
2. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
3. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
4. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
5. Recent Developments in the Maytansinoid Antitumor Agents
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Design and Synthesis of Aspirin-chalcone Mimic Conjugates as Potential Anticancer Agents;Anti-Cancer Agents in Medicinal Chemistry;2024-04
2. Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates;F1000Research;2024-03-11
3. Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents;Bioorganic Chemistry;2024-02
4. Resistance of HER2-expressing breast cancer patients treated with trastuzumab: Underlying mechanisms of resistance and reversals;Overcoming Cancers Resistant to HER-2 Antibodies;2024
5. Targeted drug delivery: concepts, approaches, and applications;Novel Formulations and Future Trends;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3